EndoBarrier treatment for longstanding type 2 diabetes and obesity: outcomes one year after EndoBarrier in 90 consecutively treated patients

• Published in: Practical diabetes (2011) 2022-05, Vol.39 (3), p.13-16a
• Main Authors: Ryder, Robert EJ, Yadagiri, Mahi, Burbridge, Wyn, Irwin, Susan P, Gandhi, Hardeep, Bashir, Tahira, Allden, Rachael A, Wyres, Melanie, Cull, Melissa, Bleasdale, John P, Fogden, Edward N, Anderson, Mark R, Gupta, Piya Sen
• Format: Article
• Language: English
• Subjects: Abscesses; bariatric surgery; diabesity; Diabetes; DJBL; duodenal–jejunal bypass liner; EndoBarrier; Endoscopy; Gastrointestinal surgery; Insulin; Obesity; Remission (Medicine); Surgical outcomes; Transplants & implants; type 2 diabetes; Weight control
• ISSN: 2047-2897; 2047-2900
• DOI: 10.1002/pdi.2393

Aims: EndoBarrier is a 60cm duodenal–jejunal bypass liner endoscopically implanted for up to one year and designed to mimic the by‐pass part of Roux‐en‐Y bariatric surgery. We aimed to assess the safety and efficacy of EndoBarrier in patients with suboptimally‐controlled diabesity. Methods: Between July 2013 and November 2017 we implanted 90 EndoBarriers in a single centre with all removed by November 2018. Outcomes were monitored in a registry. Results: All 90 patients have completed one‐year post EndoBarrier removal and, of these, 71/90 (79%) – age 51.3 ± 8.6 years, 46% male, 52% White ethnicity, diabetes duration 13.0 (7.0–17.0) years, 59% insulin‐treated, BMI 41.1 ± 6.5kg/m2) – attended follow‐up and 19/90 (21%) did not attend follow‐up. During EndoBarrier implantation, mean ± SD HbA1c fell by 19.5 ± 18.4mmol/mol from 78.1 ± 18.9 to 58.6 ± 13.6mmol/mol (p